10 Stocks With Explosive Growth Potential

6. BridgeBio Pharma Inc. (NASDAQ:BBIO)

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue to $502.1 million. This was driven largely by the commercial success of its flagship product, Attruby. In Q4 alone, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3. This growth was supported by 7,804 new patient starts and high levels of patient persistence.

The company achieved significant clinical milestones with three positive Phase 3 readouts in late 2025: Encaleret for ADH1, BBP-418 for LGMD2I, and Infigratinib for achondroplasia. These successes position BridgeBio to transition from a single-product company to one with potentially six approved medicines by the end of its first decade. NDAs for both Encaleret and BBP-418 are expected in H1 2026, with US launches targeted for late 2026 or early 2027.

Management highlighted that Attruby’s near-complete stabilization of transthyretin serves as a key clinical differentiator that should protect its market share even as potential generic competitors for tafamidis emerge. While the net loss for the year widened to $724.9 million, BridgeBio Pharma Inc. (NASDAQ:BBIO) expects cash burn to stabilize and eventually decrease as Attruby’s margins expand and new products enter the market.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases.